Skip to main content

Branded

  • Walgreens Infusion Services selected as a contracted provider of just-approved long-term treatment for SBS

    DEERFIELD, Ill. — Walgreens Infusion Services has been selected as a contracted provider of a new injectable medication that helps patients with short bowel syndrome get more — or all — of their nutrients orally, reducing their dependence on intravenous parenteral nutrition, the division announced Wednesday.

  • FDA approves new drug for short bowel syndrome

    SILVER SPRING, Md. — The Food and Drug Administration has approved a drug to treat a condition that affects people who have had their intestines partially or completely removed, the agency said Friday.

    The FDA announced the approval of NPS Pharmaceuticals' Gattex (teduglutide) for daily injection in adults with short bowel syndrome who need additional nutrition from intravenous feeding. SBS results from partial or complete surgical removal of the small or large intestine, which can lead to poor absorption of fluids and nutrients from food.

  • FDA approves biotech drug for reducing symptoms of severe chickenpox infection

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for reducing the severity of chickenpox symptoms, the agency said Friday.

    The FDA announced the approval of Cangene Corp.'s Varizig (varicella zoster immune globulin [human]) for varicella zoster, the virus that causes chickenpox. The FDA said Varizig was the only FDA-approved immune globulin for the virus after exposure.

  • FDA approves Tamiflu in children younger than 1 year

    SILVER SPRING, Md. — The Food and Drug Administration has approved a common flu drug for use in children as young as 2 weeks old, the agency said Friday.

    The FDA announced the new approval for Genentech's Tamiflu (oseltamivir). The agency said that while patients ages 1 year and older can receive the same dosage, those younger than 1 year must be dosed based on their exact weight.

  • Study finds increase in retail co-pays for prescription drugs

    PLANO, Texas — Retail co-pays for drugs are on the rise across all drug types, according to a new study by the Pharmacy Benefit Management Institute.

    The study, based on a survey of 424 U.S. employers representing about 3.7 million members, found that retail co-pays increased 10% for generics, 13% for branded drugs and 26% for specialty drugs. Meanwhile, there was an increase in use of multitier designs, which now represent 92% of plan sponsors, while adoption of medication therapy management for commercial populations was "minimal."

  • Most prescribers would pick biosimilar RA drugs

    BURLINGTON, Mass. — A majority of prescribers would prescribe biosimilar versions of two treatments for rheumatoid arthritis within a year of their approval, according to a new study.

  • FDA approves GSK four-strain flu vaccine

    LONDON — The Food and Drug Administration has approved a new four-strain flu vaccine made by GlaxoSmithKline, the drug maker said.

    GSK announced the approval of its Fluarix Quadrivalent (influenza virus vaccine) for children and adults against seasonal influenza subtypes A and B. The company said the vaccine was the first for intramuscular injection that protects against four strains of the virus.

  • Takeda to sell URL Pharma to Caraco Pharmaceutical Labs

    OSAKA, Japan — Japanese drug maker Takeda Pharmaceutical is selling its generics business to India-based Sun Pharmaceutical Industries, Takeda said Monday.

    Takeda said it would sell URL Pharma, through U.S. subsidiary Takeda Pharmaceuticals USA, to Sun subsidiary Caraco Pharmaceutical Labs while retaining control of the gout treatment Colcrys (colchicine). Takeda acquired rights to Colcrys when it bought URL Pharma for $800 million in June 2012; financial terms of the current deal with Caraco were not disclosed.

X
This ad will auto-close in 10 seconds